AMTI Stock Overview
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases.
Applied Molecular Transport Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.15|
|52 Week High||US$26.44|
|52 Week Low||US$0.85|
|1 Month Change||-16.06%|
|3 Month Change||-49.34%|
|1 Year Change||-95.37%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-93.60%|
Recent News & Updates
Applied Molecular Transport GAAP EPS of -$0.93
Applied Molecular Transport press release (NASDAQ:AMTI): Q2 GAAP EPS of -$0.93. Cash, cash equivalents and investments. As of June 30, 2022, cash and cash equivalents were $95.8 million.
Companies Like Applied Molecular Transport (NASDAQ:AMTI) Could Be Quite Risky
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Applied Molecular Transport up 4% after hours on ulcerative colitis candidate data
Shares of Applied Molecular Transport (NASDAQ:AMTI) are up ~4% in after-hours trading after the company said it will release top-line results from a phase 2 trial of AMT-101 for ulcerative colitis before Wednesday's opening bell. The trial enrolled biologic-naive patients with moderate-to-severe disease. AMT-101 was given with a TNFα inhibitor. AMT-101 is a GI-selective, oral recombinant biologic fusion protein of human interleukin 10 (hIL-10). In May, Applied Molecular implemented a cost and workforce cutting plan.
|AMTI||US Biotechs||US Market|
Return vs Industry: AMTI underperformed the US Biotechs industry which returned -20.8% over the past year.
Return vs Market: AMTI underperformed the US Market which returned -18.2% over the past year.
|AMTI Average Weekly Movement||12.4%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.0%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: AMTI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: AMTI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company’s lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects.
Applied Molecular Transport Inc. Fundamentals Summary
|AMTI fundamental statistics|
Is AMTI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AMTI income statement (TTM)|
|Cost of Revenue||US$32.83m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.46|
|Net Profit Margin||0.00%|
How did AMTI perform over the long term?See historical performance and comparison